Market LIVE
Published markets; coverage varies by country
Product profile · United States

Zymfentra

 ·  Patent Litigation & Settlement History ↓

Ingredientinfliximab-dyyb
Application typeBLA
Application761358
Product001
Dosage formInjection
RouteSubcutaneous
Strength120MG/ML
Approval date2023-10-20
Marketing statusPrescription
Status event—
ApplicantCELLTRION
Product source

Current GenericRadar decision

Year2035
SelectionDEEP_REVIEW
ReviewFINAL_CHECKING
Anchor typeREGULATORY_EXCLUSIVITY
Anchor date2035-10-20
Patent anchor—
Exclusivity anchor2035-10-20
Protection date—
First Final ANDA—
Status event—

{"sequence":272,"product_key":"US:BLA:761358:001","judgment_status":"PROVISIONAL_EVIDENCE_SCREEN","review_basis":"LATER_RIGHT_SIGNAL","reason_codes":["LATER_PATENT_REFERENCE_DATE: US11951207"],"unknown_patent_terms":[],"pending_publications":[],"regulatory_anchor":"2035-10-20","later_regulatory_events":[],"batch":"BLA-05-06","review_version":"1.1","selection_status":"DEEP_REVIEW","verified":false,"anchor_status":"OPERATIONAL_UNVERIFIED","rights_anchor_date":"2035-10-20","patent_anchor_numbers":[],"patent_term_verified":false,"canonical_judgment_confirmed":false,"first_biosimilar_approval_date":null,"first_final_generic_date":null,"has_existing_generic":null,"has_existing_biosimilar":null,"report":"BLA_05_06_50_JUDGMENT_20261021.html","report_sha256":"d3f5cba95e750a9f93f53184cc6d1c82c363bb5bb718ddbc60ccfe5c14efed29","regulatory_update_pending":true,"local_patent_review_pending":true,"FDA_followup":[{"issue":"FDA_RPE_DETERMINATION_AND_END_DATE_NOT_LOCATED","status":"UPDATE_PENDING","reason":"FDA PB target fields remain blank; no additional exact-target final determination located in the retrieved public FDA letters/review/administrative documents. Orange Book has no target BLA rows. Operational baseline retained with verified=false."}],"tail_patents":["US11951207"]}

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
US119512072038-08-03— —NNDP_NON_DS
{"classification":"DP_NON_DS","claim_count":14,"claim_number_coverage_complete":true,"reference_date_only":true,"official_current_term_verified":false,"commercial_product_mapping":"NOT_ESTABLISHED","batch":"BLA-05-06"}
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
ODE1998-08-242005-08-24NN——Source
ODE2006-05-192013-05-19NN——Source
ODE2011-09-232018-09-23NN——Source
RPE_BASELINE2023-10-202035-10-20Full-product 12-year operational assumption; not FDA determinationYY——Source

2026-10-10 · PENDING_EXCLUSIVITY_CONFIRMATION · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (5)
TypeDateRoleBasisSource
PATENT2038-08-03OTHER_RIGHT_REFERENCEProduct scope reviewed; reference date only; current official term verification pendingSource
REGULATORY_EXCLUSIVITY2005-08-24SCOPE_HISTORYIndication-specific history; full coverage not assertedSource
REGULATORY_EXCLUSIVITY2013-05-19SCOPE_HISTORYIndication-specific history; full coverage not assertedSource
REGULATORY_EXCLUSIVITY2018-09-23SCOPE_HISTORYIndication-specific history; full coverage not assertedSource
REGULATORY_EXCLUSIVITY2035-10-20ANCHOR_CALCULATIONUser-adopted operational baseline; inherited dates do not restart RPE; not FDA determinationSource
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.